However, this strategy is only attractive if the therapeutic agent itself is not a substrate for CPA, or if the case, that its functional activity is not negatively affected by C-terminal cleavage
Weight loss from microdosing is likely modest and short-term, highly variable, and not guaranteedand there is still the problem of long-term maintenance if new habits are not adopted and the drug is discontinued, Zimmermann says
GLP-1 receptor agonists like semaglutide were originally developed to treat type 2 diabetes, and decades of safety data show these medications can be used continuously for extended periods
If you miss one dose, it is best to resume use as soon as possible
I did my homework, found a reputable Canadian source, and made the switch in January
A history of heart attack, stroke, angina, coronary artery disease, or peripheral arterial disease qualifies